Aptose Biosciences Inc., of San Diego, reported preclinical data at the American Association for Cancer Research conference in Boston demonstrating that CG'806, a pan-FLT3/BTK inhibitor, exerts activity against acute myeloid leukemia (AML) cells harboring mutant forms of FLT3 and eradicates AML tumors in a murine xenograft model.